Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Account Payables (2016 - 2025)

Mimedx's Change in Account Payables history spans 14 years, with the latest figure at -$1.6 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 322.44% year-over-year to -$1.6 million; the TTM value through Dec 2025 reached $2.1 million, up 250.28%, while the annual FY2025 figure was $2.1 million, 250.28% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$1.6 million at Mimedx, down from $2.9 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.7 million in Q2 2021 and bottomed at -$3.6 million in Q3 2021.
  • The 5-year median for Change in Account Payables is $175000.0 (2023), against an average of $108600.0.
  • The largest annual shift saw Change in Account Payables surged 6878.57% in 2023 before it plummeted 330.68% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $669000.0 in 2021, then tumbled by 137.52% to -$251000.0 in 2022, then soared by 126.69% to $67000.0 in 2023, then surged by 964.18% to $713000.0 in 2024, then crashed by 322.44% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Change in Account Payables are -$1.6 million (Q4 2025), $2.9 million (Q3 2025), and -$668000.0 (Q2 2025).